{
     "PMID": "25524173",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160415",
     "LR": "20170220",
     "IS": "1750-1326 (Electronic) 1750-1326 (Linking)",
     "VI": "9",
     "DP": "2014 Dec 18",
     "TI": "Andrographolide reduces cognitive impairment in young and mature AbetaPPswe/PS-1 mice.",
     "PG": "61",
     "LID": "10.1186/1750-1326-9-61 [doi]",
     "AB": "Alzheimer's disease (AD) is a neurodegenerative disorder in which the amyloid-beta (Abeta) oligomers are a key factor in synaptic impairment and in spatial memory decline associated with neuronal dysfunction. This impairment includes synaptic failure associated with the loss of synaptic proteins that contribute to AD progression. Interestingly, the use of natural compounds is an emergent conceptual strategy in the search for drugs with therapeutic potentials for treating neurodegenerative disorders. In the present study, we report that andrographolide (ANDRO), which is a labdane diterpene extracted from Andrographis paniculata, increases slope of field excitatory postsynaptic potentials (fEPSP) in the CA1 region of hippocampal slices and inhibits long-term depression (LTD), protecting the long-term potentiation (LTP) against the damage induced by Abeta oligomers in vitro, most likely by inhibiting glycogen synthase kinase-3beta (GSK-3beta). Additionally, ANDRO prevents changes in neuropathology in two different age groups (7- and 12-month-old mice) of an AbetaPPswe/PS-1 Alzheimer's model. ANDRO reduces the Abeta levels, changing the ontogeny of amyloid plaques in hippocampi and cortices in 7-month-old mice, and reduces tau phosphorylation around the Abeta oligomeric species in both age groups. Additionally, we observed that ANDRO recovers spatial memory functions that correlate with protecting synaptic plasticity and synaptic proteins in two different age groups. Our results suggest that ANDRO could be used in a potential preventive therapy during AD progression.",
     "FAU": [
          "Serrano, Felipe G",
          "Tapia-Rojas, Cheril",
          "Carvajal, Francisco J",
          "Hancke, Juan",
          "Cerpa, Waldo",
          "Inestrosa, Nibaldo C"
     ],
     "AU": [
          "Serrano FG",
          "Tapia-Rojas C",
          "Carvajal FJ",
          "Hancke J",
          "Cerpa W",
          "Inestrosa NC"
     ],
     "AD": "Centro de Envejecimiento y Regeneracion (CARE), Santiago, Chile. faserran@uc.cl. Centro de Envejecimiento y Regeneracion (CARE), Santiago, Chile. cheril.tapia@gmail.com. Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile. fvcarvajal@uc.cl. Instituto de Farmacologia y Morfofisiologia, Universidad Austral de Chile, Valdivia, Chile. jhanckeo@gmail.com. Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile. wcerpa@bio.puc.cl. Centro de Envejecimiento y Regeneracion (CARE), Santiago, Chile. ninestrosa@bio.puc.cl. Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile. ninestrosa@bio.puc.cl. Center of Healthy Brain Aging, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia. ninestrosa@bio.puc.cl. Centro UC Sindrome de Down, Pontificia Universidad Catolica de Chile, Santiago, Chile. ninestrosa@bio.puc.cl. Centro de Excelencia en Biomedicina de Magallanes (CEBIMA), Universidad de Magallanes, Punta Arenas, Chile. ninestrosa@bio.puc.cl. CARE Biomedical Center, P. Catholic University of Chile, Postal code 8331150, PO Box 114-D, Santiago, Chile. ninestrosa@bio.puc.cl.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20141218",
     "PL": "England",
     "TA": "Mol Neurodegener",
     "JT": "Molecular neurodegeneration",
     "JID": "101266600",
     "RN": [
          "0 (Anti-Inflammatory Agents, Non-Steroidal)",
          "0 (Diterpenes)",
          "410105JHGR (andrographolide)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/*pathology",
          "Animals",
          "Anti-Inflammatory Agents, Non-Steroidal/*pharmacology",
          "Cognition Disorders/*pathology",
          "Disease Models, Animal",
          "Diterpenes/*pharmacology",
          "Excitatory Postsynaptic Potentials/drug effects",
          "Hippocampus/*drug effects/pathology",
          "Immunohistochemistry",
          "Long-Term Potentiation/drug effects",
          "Male",
          "Maze Learning/drug effects",
          "Mice",
          "Mice, Transgenic",
          "Patch-Clamp Techniques"
     ],
     "PMC": "PMC4414355",
     "EDAT": "2014/12/20 06:00",
     "MHDA": "2016/04/16 06:00",
     "CRDT": [
          "2014/12/20 06:00"
     ],
     "PHST": [
          "2014/08/22 00:00 [received]",
          "2014/12/06 00:00 [accepted]",
          "2014/12/20 06:00 [entrez]",
          "2014/12/20 06:00 [pubmed]",
          "2016/04/16 06:00 [medline]"
     ],
     "AID": [
          "10.1186/1750-1326-9-61 [doi]",
          "1750-1326-9-61 [pii]"
     ],
     "PST": "epublish",
     "SO": "Mol Neurodegener. 2014 Dec 18;9:61. doi: 10.1186/1750-1326-9-61.",
     "term": "hippocampus"
}